Understanding the phosphoantigen, butyrophilin, and γ9δ2 T cell axis.
文献摘要
The γ9δ2 T cells act at the intersection of innate and adaptive immunity to rapidly respond to infections and cancer. Over the past few decades, pivotal discoveries have clarified the mechanisms by which microbial and endogenous phosphoantigens (pAgs) bind to butyrophilins (BTNs), inducing conformational and clustering changes that facilitate γ9δ2 T cell activation. These discoveries involve advances in understanding pAg structure-activity relationships and identification of new natural and synthetic pAgs with diverse binding modes. Molecular and structural biology studies have led to the elucidation of the architecture of BTN complexes, such as the 3A1-3A2-(2A1) 2 complex for (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) detection and the (3A3) 2 -(2A1) 2 complex for mevalonate diphosphate (MPP) detection, and their engagement with γ9δ2 T cell receptors. Clinically, γ9δ2 T cells are being explored using synthetic pAgs, bisphosphonates, and BTN antibodies to expand and activate these cells. In this review, we examine the major milestones in research on the pAg, BTN, and γ9δ2 T cell axis, highlighting its significance to human cancers.